These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 3480670)

  • 1. [CA 19-9 and CA 125 in hepatobiliary pathology].
    Preux C; Gerard M; Delhange A; Bondue H; Delcourt A
    Acta Gastroenterol Belg; 1987; 50(1):45-51. PubMed ID: 3480670
    [No Abstract]   [Full Text] [Related]  

  • 2. Independent expression in serum of three tumour-associated antigens: CA 125, placental alkaline phosphatase and HMFG2 in ovarian carcinoma.
    Ward BG; Cruickshank DJ; Tucker DF; Love S
    Br J Obstet Gynaecol; 1987 Jul; 94(7):696-8. PubMed ID: 2441739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Serum levels and clinical evaluation of CA 19-9 in various diseases].
    Toyama K; Noto M; Sakaguchi T; Adachi K; Mitomi H; Okada N; Ootaka H; Nakazawa H; Hara E
    Gan No Rinsho; 1985 Mar; 31(3):293-8. PubMed ID: 2582158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Carbohydrate antigen (CA-19-9) in the blood serum of patients with benign and malignant liver diseases].
    Ametov AS; Kasatkin IuN; Mit'kov VV; Gur'eva IV
    Med Radiol (Mosk); 1985 Mar; 30(3):39-41. PubMed ID: 3856723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor markers carbohydrate antigens CA 19-9 and CA-50 and carcinoembryonic antigen in pancreatic cancer and benign diseases of the pancreatobiliary tract.
    Harmenberg U; Wahren B; Wiechel KL
    Cancer Res; 1988 Apr; 48(7):1985-8. PubMed ID: 3349472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How does liver dysfunction influence serum CA 19-9 in pancreatic cancer?
    Basso D; Fabris C; Del Favero G; Piccoli A; Angonese C; Pasquali C; Castoro C; Plebani M; Leandro G; Burlina A
    Ital J Gastroenterol; 1990 Feb; 22(1):1-6. PubMed ID: 2131920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical value of serum tumour markers CEA, CA 50 and CA 242 in the distinction between malignant versus benign diseases causing jaundice and cholestasis; results from a prospective study.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Anticancer Res; 1992; 12(5):1687-93. PubMed ID: 1332581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [CA 19-9 and cancer of the pancreas. Critical review of the literature].
    Delcourt A
    Acta Gastroenterol Belg; 1987; 50(1):1-8. PubMed ID: 3321822
    [No Abstract]   [Full Text] [Related]  

  • 9. [Clinical significance of CA 19-9 as a tumor marker for gynecologic malignancies].
    Inoue M; Saitoh J; Abe Y; Inoue Y; Ueda G; Tanizawa O; Gamoh Y; Dan A; Satoh T
    Nihon Sanka Fujinka Gakkai Zasshi; 1985 Nov; 37(11):2411-4. PubMed ID: 3865972
    [No Abstract]   [Full Text] [Related]  

  • 10. [Significance of the serum levels of Ca 19-9 and CA 50 in gastric cancer].
    Loizate Totorikaguena A; Lamiquiz Vallejo A; Domínguez Merru-Urrutia MJ
    Rev Esp Enferm Apar Dig; 1987 Nov; 72(5 Pt 2):644-5. PubMed ID: 2452465
    [No Abstract]   [Full Text] [Related]  

  • 11. [CA 19-9 in neoplasms. Comparison with CEA].
    Nakad A; Jonard P; Geubel A; Warzee P; Coppens JP; Dehennin JP; Dive C
    Acta Gastroenterol Belg; 1987; 50(1):36-44. PubMed ID: 3480669
    [No Abstract]   [Full Text] [Related]  

  • 12. [Value of CA 125 in comparison to conventional tumor markers in ovarian cancer].
    Paulick R; Kaesemann H; Caffier H
    Geburtshilfe Frauenheilkd; 1986 Aug; 46(8):509-14. PubMed ID: 2875919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Serum CA-125 level in patients with gynecologic tumors].
    Abe Y; Ueda G; Yamasaki M; Inoue M; Hiramatsu K; Inoue Y; Saito J; Nishino T
    Rinsho Byori; 1984 Dec; 32(12):1350-4. PubMed ID: 6597876
    [No Abstract]   [Full Text] [Related]  

  • 14. [CA 19-9 in benign diseases of the gastrointestinal tract].
    Klapdor R
    Dtsch Med Wochenschr; 1986 Jun; 111(26):1039. PubMed ID: 3459644
    [No Abstract]   [Full Text] [Related]  

  • 15. The structure of the Ca-antigen.
    Wiseman G; Bramwell ME; Bhavanandan VP; Harris H
    Biochem Soc Trans; 1984 Jun; 12(3):537-8. PubMed ID: 6588010
    [No Abstract]   [Full Text] [Related]  

  • 16. Cross-specificity of the tumour marker CA 19-9: a case of ovarian carcinoma with recurrent venous thrombosis.
    Smellie S; Lambert M
    Acta Gastroenterol Belg; 1987; 50(2):241-2. PubMed ID: 3481507
    [No Abstract]   [Full Text] [Related]  

  • 17. Serum levels of CA-125 in patients with endometriosis.
    Giudice LC; Jacobs AJ; Bell CE; Lippmann L
    Gynecol Oncol; 1986 Oct; 25(2):256-8. PubMed ID: 3463522
    [No Abstract]   [Full Text] [Related]  

  • 18. [Behavior of serum CA 125 in hepatopathy patients].
    Ruibal A; Encabo G; Capdevila JA; Aguadé S; Gefaell R; Ribera E; Martínez-Vázquez JM
    Med Clin (Barc); 1984 Mar; 82(12):560. PubMed ID: 6738156
    [No Abstract]   [Full Text] [Related]  

  • 19. CA 19-9 in non-neoplastic liver diseases. A clinical and laboratory study.
    Collazos J; Genolla J; Ruibal A
    Clin Chim Acta; 1992 Sep; 210(1-2):145-51. PubMed ID: 1424156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of hepatic dysfunction and bilirubin on CA 19-9 levels in cirrhotic patients.
    Leandro G; Zizzari S; Manghisi OG
    Gastroenterology; 1987 Jan; 92(1):270-1. PubMed ID: 3465665
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.